Emrelis™ (telisotuzumab vedotin-tllv)
for Lung Cancer

Emrelis is an antibody-drug conjugate targeting c-Met, used to treat adults with locally advanced or metastatic non-squamous NSCLC showing high c-Met overexpression (≥50% of tumor cells with strong staining), as confirmed by an FDA-approved test, after prior systemic therapy.

Heart
Other top medicines used to treat Lung Cancer